Total Payments
$158,375
2024 Payments
$2,596
Companies
13
Transactions
88
Medicare Patients
547
Medicare Billing
$80,488
Payment Breakdown by Category
Consulting$60,755 (38.4%)
Research$44,367 (28.0%)
Education$26,170 (16.5%)
Other$19,006 (12.0%)
Travel$6,684 (4.2%)
Food & Beverage$1,393 (0.9%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $60,755 | 20 | 38.4% |
| Unspecified | $44,367 | 14 | 28.0% |
| Education | $26,170 | 3 | 16.5% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $14,506 | 11 | 9.2% |
| Travel and Lodging | $6,684 | 18 | 4.2% |
| Honoraria | $4,500 | 1 | 2.8% |
| Food and Beverage | $1,393 | 21 | 0.9% |
Payments by Type
General
$114,008
74 transactions
Research
$44,367
14 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., Inc. | $46,039 | 9 | $0 (2019) |
| Celgene Corporation | $30,766 | 16 | $0 (2022) |
| Novartis Pharmaceuticals Corporation | $27,858 | 13 | $0 (2024) |
| E.R. Squibb & Sons, L.L.C. | $23,259 | 16 | $0 (2023) |
| PFIZER INC. | $10,206 | 10 | $0 (2019) |
| La Jolla Pharmaceutical Company | $6,831 | 6 | $0 (2018) |
| GlaxoSmithKline, LLC. | $6,200 | 10 | $0 (2022) |
| F. Hoffmann-La Roche AG | $3,252 | 2 | $0 (2024) |
| Kyowa Kirin, Inc. | $1,875 | 1 | $0 (2022) |
| ImClone Systems, LLC | $850.00 | 1 | $0 (2018) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $2,596 | 4 | F. Hoffmann-La Roche AG ($1,057) |
| 2023 | $8,495 | 4 | E.R. Squibb & Sons, L.L.C. ($3,855) |
| 2022 | $8,239 | 15 | GlaxoSmithKline, LLC. ($6,200) |
| 2021 | $14,522 | 6 | Novartis Pharmaceuticals Corporation ($13,100) |
| 2020 | $27,481 | 7 | Celgene Corporation ($20,739) |
| 2019 | $59,015 | 18 | Takeda Pharmaceuticals U.S.A., Inc. ($46,039) |
| 2018 | $23,937 | 26 | E.R. Squibb & Sons, L.L.C. ($9,098) |
| 2017 | $14,089 | 8 | E.R. Squibb & Sons, L.L.C. ($10,306) |
All Payment Transactions
88 individual payment records from CMS Open Payments — Page 1 of 4
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 09/28/2024 | Novartis Pharma AG | SCEMBLIX (Drug) | — | In-kind items and services | $391.86 | Research |
| Study: CABL001X2101 • Category: ONCOLOGY | ||||||
| 05/08/2024 | Novartis Pharma AG | SCEMBLIX (Drug) | — | In-kind items and services | $162.05 | Research |
| Study: CABL001X2101 • Category: ONCOLOGY | ||||||
| 03/31/2024 | F. Hoffmann-La Roche AG | — | — | In-kind items and services | $1,056.59 | Research |
| Study: Phase 2 Study Of PRM 151 In Subjects With Myelofibrosis | ||||||
| 03/08/2024 | Novartis Pharmaceuticals Corporation | SCEMBLIX (Drug) | — | Cash or cash equivalent | $985.68 | Research |
| Study: CABL001X2101 • Category: Oncology | ||||||
| 12/31/2023 | F. Hoffmann-La Roche AG | — | — | In-kind items and services | $2,195.44 | Research |
| Study: Phase 2 Study Of PRM 151 In Subjects With Myelofibrosis | ||||||
| 10/19/2023 | NOVARTIS PHARMACEUTICALS CORPORATION | — | Consulting Fee | Cash or cash equivalent | $1,856.25 | General |
| 08/01/2023 | Novartis Pharmaceuticals Corporation | — | — | Cash or cash equivalent | $588.77 | Research |
| Study: CABL001X2101 | ||||||
| 01/25/2023 | E.R. Squibb & Sons, L.L.C. | INREBIC (Drug) | Consulting Fee | Cash or cash equivalent | $3,854.50 | General |
| Category: Hematology | ||||||
| 12/09/2022 | Celgene Corporation | INREBIC (Drug) | Food and Beverage | Cash or cash equivalent | $41.00 | General |
| Category: Hematology | ||||||
| 12/09/2022 | Celgene Corporation | INREBIC (Drug) | Food and Beverage | Cash or cash equivalent | $41.00 | General |
| Category: Hematology | ||||||
| 12/09/2022 | Celgene Corporation | INREBIC (Drug) | Food and Beverage | Cash or cash equivalent | $41.00 | General |
| Category: Hematology | ||||||
| 12/09/2022 | Celgene Corporation | INREBIC (Drug) | Food and Beverage | Cash or cash equivalent | $41.00 | General |
| Category: Hematology | ||||||
| 10/27/2022 | GlaxoSmithKline, LLC. | — | Consulting Fee | Cash or cash equivalent | $4,000.00 | General |
| 10/27/2022 | GlaxoSmithKline, LLC. | — | Travel and Lodging | Cash or cash equivalent | $52.00 | General |
| 10/27/2022 | GlaxoSmithKline, LLC. | — | Travel and Lodging | Cash or cash equivalent | $52.00 | General |
| 10/27/2022 | GlaxoSmithKline, LLC. | — | Food and Beverage | Cash or cash equivalent | $10.57 | General |
| 10/14/2022 | GlaxoSmithKline, LLC. | — | Travel and Lodging | In-kind items and services | $289.92 | General |
| 10/14/2022 | GlaxoSmithKline, LLC. | — | Food and Beverage | In-kind items and services | $82.49 | General |
| 10/14/2022 | GlaxoSmithKline, LLC. | — | Food and Beverage | In-kind items and services | $72.92 | General |
| 10/09/2022 | GlaxoSmithKline, LLC. | — | Travel and Lodging | In-kind items and services | $198.83 | General |
| 10/09/2022 | GlaxoSmithKline, LLC. | — | Travel and Lodging | In-kind items and services | $191.24 | General |
| 10/01/2022 | GlaxoSmithKline, LLC. | — | Consulting Fee | Cash or cash equivalent | $1,250.00 | General |
| 02/22/2022 | Kyowa Kirin, Inc. | — | Consulting Fee | Cash or cash equivalent | $1,875.00 | General |
| 10/12/2021 | Novartis Pharmaceuticals Corporation | — | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,930.00 | General |
| 08/17/2021 | Novartis Pharmaceuticals Corporation | — | Consulting Fee | Cash or cash equivalent | $2,620.00 | General |
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| An Open-Label, Dose-Escalation, Phase 1-2 Study of the Oral Formulation of MLN9708 Administered Twice-weekly in Combination with Lenalidomide and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Requiring Systemic Treatment | Takeda Pharmaceuticals U.S.A., Inc. | $36,554 | 4 |
| Phase 2 Study Of PRM 151 In Subjects With Myelofibrosis | F. Hoffmann-La Roche AG | $3,252 | 2 |
| CABL001X2101 | Novartis Pharmaceuticals Corporation | $1,574 | 2 |
| A Phase 3b, Multicenter, Single-Arm, Open-Label Efficacy & Safety Study of Fedratinib in Subjects w/ DIPSS-Intermediate or High-Risk PMF, post-PV MF, or post-ET MF & Previously Treated w/ Ruxolitinib incl. Sub-study w/ concomitant Luspatercept for anemia (FEDR-MF-001) | Celgene Corporation | $952.00 | 1 |
| CABL001X2101 | Novartis Pharma AG | $553.91 | 2 |
| Phase II, Open Label, Single Arm Study of SAR302503 In Myelofibrosis Patients Previously Treated With Ruxolitinib | SANOFI-AVENTIS U.S. LLC | $463.39 | 1 |
| RESEARCH RELATED PUBLICATIONS SUPPORT | Novartis Pharmaceuticals Corporation | $168.00 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 3 | 116 | 173 | $38,548 | $15,947 |
| 2022 | 2 | 135 | 238 | $40,712 | $22,734 |
| 2021 | 2 | 159 | 240 | $42,696 | $23,073 |
| 2020 | 1 | 137 | 219 | $40,350 | $18,735 |
Total Patients
547
Total Services
870
Medicare Billing
$80,488
Procedure Codes
9
All Medicare Procedures & Services
9 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2023 | 89 | 141 | $32,947 | $13,758 | 41.8% |
| 99443 | Telephone medical discussion with physician, 21-30 minutes | Office | 2023 | 14 | 17 | $2,245 | $1,105 | 49.2% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2023 | 13 | 15 | $3,356 | $1,084 | 32.3% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2022 | 104 | 197 | $35,567 | $20,248 | 56.9% |
| 99443 | Telephone medical discussion with physician, 21-30 minutes | Office | 2022 | 31 | 41 | $5,145 | $2,485 | 48.3% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Facility | 2021 | 106 | 177 | $31,374 | $18,240 | 58.1% |
| 99443 | Physician telephone patient service, 21-30 minutes of medical discussion | Office | 2021 | 53 | 63 | $11,322 | $4,833 | 42.7% |
| 99215 | Established patient office or other outpatient, visit typically 40 minutes | Facility | 2020 | 98 | 172 | $30,406 | $14,588 | 48.0% |
| 99215 | Established patient office or other outpatient, visit typically 40 minutes | Office | 2020 | 39 | 47 | $9,944 | $4,147 | 41.7% |
About Dr. Moshe Talpaz, MD
Dr. Moshe Talpaz, MD is a Internal Medicine healthcare provider based in Ann Arbor, Michigan. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 10/31/2006. The National Provider Identifier (NPI) number assigned to this provider is 1801972773.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Moshe Talpaz, MD has received a total of $158,375 in payments from pharmaceutical and medical device companies, with $2,596 received in 2024. These payments were reported across 88 transactions from 13 companies. The most common payment nature is "Consulting Fee" ($60,755).
As a Medicare-enrolled provider, Talpaz has provided services to 547 Medicare beneficiaries, totaling 870 services with total Medicare billing of $80,488. Data is available for 4 years (2020–2023), covering 9 distinct procedure/service records.
Ad
Practice Information
- Specialty Internal Medicine
- Other Specialties Medical Oncology
- Location Ann Arbor, MI
- Active Since 10/31/2006
- Last Updated 04/19/2012
- Taxonomy Code 207R00000X
- Entity Type Individual
- NPI Number 1801972773
Products in Payments
- Revlimid (Drug) $36,554
- INREBIC (Drug) $21,758
- SPRYCEL (Drug) $15,565
- ICLUSIG (Drug) $9,485
- Fedratinib (Drug) $7,888
- DAURISMO (Drug) $6,780
- ABL002 (Drug) $4,753
- TASIGNA (Drug) $3,930
- OPDIVO (Biological) $3,840
- REBLOZYL (Biological) $3,000
- SCEMBLIX (Drug) $1,540
- BOSULIF (Drug) $700.00
- Inrebic (Drug) $476.00
- JAK-2 (Drug) $463.39
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Internal Medicine Doctors in Ann Arbor
Dr. Marschall Runge, Md, MD
Internal Medicine — Payments: $2.3M
Internal Medicine $2.3M
Terry Smith, M.d, M.D
Internal Medicine — Payments: $2.1M
Internal Medicine $2.1M
Harry Erba, Md, MD
Internal Medicine — Payments: $1.8M
Internal Medicine $1.8M
Dr. Dinesh Khanna, M.d, M.D
Internal Medicine — Payments: $1.2M
Internal Medicine $1.2M
Alexander Yevzlin, Md, MD
Internal Medicine — Payments: $1.2M
Internal Medicine $1.2M
Vallerie Mclaughlin, Md, MD
Internal Medicine — Payments: $1.1M
Internal Medicine $1.1M